Latigo Biotherapeutics (NASDAQ:LTGO) Reaches New 1-Year High – Should You Buy?

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) shares reached a new 52-week high during trading on Thursday . The company traded as high as $25.22 and last traded at $24.99, with a volume of 24875 shares changing hands. The stock had previously closed at $24.13.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Latigo Biotherapeutics to a “hold” rating in a research report on Saturday, August 15th.

Latigo Biotherapeutics Stock Down 3.1%

Insider Activity at Latigo Biotherapeutics

In other Latigo Biotherapeutics news, major shareholder Foresite Capital Management V, acquired 140,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the acquisition, the insider owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James B. Tananbaum bought 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the acquisition, the director owned 2,008,024 shares in the company, valued at $36,144,432. This represents a 7.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.